These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7593134)

  • 1. Symposium on health economics in oncology. Freiburg, Germany, June 1995.
    Kranich AL; Gastl G; Druckrey E; Porzsolt F
    J Cancer Res Clin Oncol; 1995; 121(11):691-3. PubMed ID: 7593134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rationing in German health care with particular consideration of oncology: view points of German stakeholders--a qualitative interview study].
    Lange J; Gönner C; Vollmann J; Rauprich O
    Gesundheitswesen; 2015 Jan; 77(1):8-15. PubMed ID: 24696371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The origin of informed consent].
    Mallardi V
    Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Economic limits in oncology].
    Hellriegel KP
    Z Arztl Fortbild Qualitatssich; 2000 Dec; 94(10):833-6. PubMed ID: 11190919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacoeconomics in uro-oncology: the concept of QALYs].
    Poulsen Nautrup B
    Urologe A; 2011 Dec; 50(12):1573-7. PubMed ID: 22159702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Making Medical Spending Decisions: The Law, Ethics, and Economics of Rationing Mechanisms, by Mark A. Hall.
    Snyder JW
    J Leg Med; 1998 Mar; 19(1):143-50. PubMed ID: 11645054
    [No Abstract]   [Full Text] [Related]  

  • 12. [Oncology caught between economics and efficiency].
    Keil TU
    Med Klin (Munich); 2000 Jun; 95 Suppl 1():1. PubMed ID: 10941245
    [No Abstract]   [Full Text] [Related]  

  • 13. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A proposal for reforming psychologists' training in France and in the European Union].
    Bouchard JP
    Encephale; 2009 Feb; 35(1):18-24. PubMed ID: 19250989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Decision-analytical modelling of costs per QALY in the context of the German Social Law].
    Rogowski WH; Landauer M; John J
    Gesundheitswesen; 2009 Nov; 71(11):739-50. PubMed ID: 19551622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan.
    Arai H; Ouchi Y; Toba K; Endo T; Shimokado K; Tsubota K; Matsuo S; Mori H; Yumura W; Yokode M; Rakugi H; Ohshima S
    Geriatr Gerontol Int; 2015 Jun; 15(6):673-87. PubMed ID: 25656311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation as institution: a contractarian argument for needs-based economic evaluation.
    Rogowski WH
    BMC Med Ethics; 2018 Jun; 19(1):59. PubMed ID: 29895268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of cancer therapy from the perspective of a statutory health insurance].
    Rebscher H; Schellhammer S; Kopp T; Scharnetzky E
    Urologe A; 2011 Dec; 50(12):1584-90. PubMed ID: 22159704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis in oncology.
    Earle CC; Coyle D; Evans WK
    Ann Oncol; 1998 May; 9(5):475-82. PubMed ID: 9653486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The reality of economics for oncologists.
    Taylor D
    Breast; 2017 Jun; 33():183-190. PubMed ID: 28432979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.